Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis

Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study

(2016) Y. Tanaka et al.   JOURNAL OF RHEUMATOLOGY

Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients

(2015) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

SP0027 One for All – Patient Research Partners Involved in Disseminating Eular Recommendations Among Belgium Patients

(2015) I. De Keyser   ANNALS OF THE RHEUMATIC DISEASES

Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)

(2015) Xiaoshan Min et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Super-enhancers delineate disease-associated regulatory nodes in T cells

(2015) Golnaz Vahedi et al.   NATURE

ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation

(2015) Henrik M. Hammarén et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

(2015) Mark C. Genovese et al.   Arthritis & Rheumatology

OP0253 The JAK Inhibitor Tofacitinib Suppresses Synovial JAK1-STAT1 Signalling in Rheumatoid Arthritis

(2014) D. L. Boyle et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro

(2014) Sheau-Pey Wang et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

(2014) Gerd-Rűdiger Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

The molecular regulation of Janus kinase (JAK) activation

(2014) Jeffrey J. Babon et al.   BIOCHEMICAL JOURNAL

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts

(2014) M. Onda et al.   JOURNAL OF IMMUNOLOGY

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

(2014) J. Wollenhaupt et al.   JOURNAL OF RHEUMATOLOGY

Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events

(2014) Koshiro Sonomoto et al.   RHEUMATOLOGY

Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets

(2014) D. E. Furst et al.   RHEUMATOLOGY

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells

(2013) Satoshi Kubo et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

(2013) L. Van Rompaey et al.   JOURNAL OF IMMUNOLOGY

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?

(2012) Yoshiya Tanaka   ANNALS OF THE RHEUMATIC DISEASES

Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors

(2012) Anna Yarilina et al.   ARTHRITIS AND RHEUMATISM

Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators

(2012) Bernd Bodenmiller et al.   NATURE BIOTECHNOLOGY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

(2011) Sanna Rosengren et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells

(2011) Keisuke Maeshima et al.   ARTHRITIS AND RHEUMATISM

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2011) Yoshiya Tanaka et al.   ARTHRITIS CARE & RESEARCH

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Rheumatoid arthritis

(2010) David L Scott et al.   LANCET

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM